Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial (vol 14, pg 563, 2014)

被引：0
|
作者：
Mfinanga, S. G.
Kirenga, B. J.
Chanda, D. M.
机构：
来源：
LANCET INFECTIOUS DISEASES | 2014年 / 14卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：793 / 793
页数：1
相关论文
共 4 条
  • [1] Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial
    Mfinanga, Sayoki G.
    Kirenga, Bruce J.
    Chanda, Duncan M.
    Mutayoba, Beatrice
    Mthiyane, Thuli
    Yimer, Getnet
    Ezechi, Oliver
    Connolly, Cathy
    Kapotwe, Vincent
    Muwonge, Catherine
    Massaga, Julius
    Sinkala, Edford
    Kohi, Wanze
    Lyantumba, Lucinda
    Nyakoojo, Grace
    Luwaga, Henry
    Doulla, Basra
    Mzyece, Judith
    Kapata, Nathan
    Vahedi, Mahnaz
    Mwaba, Peter
    Egwaga, Saidi
    Adatu, Francis
    Pym, Alex
    Joloba, Moses
    Rustomjee, Roxana
    Zumla, Alimuddin
    Onyebujoh, Philip
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 563 - 571
  • [2] Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial (vol 14, pg 281, 2014)
    Grinsztejn, B.
    Hosseinipour, M. C.
    Ribaudo, H. J.
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (04): : 269 - 269
  • [3] Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial
    François-Xavier Blanc
    Thim Sok
    Didier Laureillard
    Laurence Borand
    Claire Rekacewicz
    Eric Nerrienet
    Yoann Madec
    Olivier Marcy
    Sarin Chan
    Narom Prak
    Chindamony Kim
    Khemarin Kim Lak
    Chanroeurn Hak
    Bunnet Dim
    Chhun Im Sin
    Sath Sun
    Bertrand Guillard
    Borann Sar
    Sirenda Vong
    Marcelo Fernandez
    Lawrence Fox
    Jean-François Delfraissy
    Anne E Goldfeld
    [J]. BMC Proceedings, 5 (Suppl 1)
  • [4] Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial (vol 383, pg 1474, 2014)
    [J]. LANCET, 2014, 383 (9927): : 1464 - 1464
1